Heyholder
‹ Activism Filings

DongKook Life Science Co., Ltd. Q3 revenue KRW 26.5 billion, operating loss of KRW 1.6 billion after a swing to loss

DongKook Life Science Co., Ltd.· Periodic Report

AI summary · Not investment advice

In Q3 the company sold KRW 26.5 billion of goods and lost KRW 1.6 billion from its main business, after a profit in the same period last year.

Operating profit · 3 months

KRW -1.6 billion

Key facts

Revenue (3 months)
KRW 26.5 billion
Net income (3 months)
KRW -506.1 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 29.4 billion
Revenue (year to date)
KRW 83.9 billion
Operating profit (prior-year 3 months)
KRW 4.3 billion
Operating profit (year to date)
KRW 1.9 billion
Net income (prior-year 3 months)
KRW 2.4 billion
Net income (year to date)
KRW 911.8 million

Commentary

AI commentary · Not investment advice

What happened

Dongkook Life Science reported its separate-basis results for the third quarter of 2026 in its quarterly report. Sales for the 3 months were KRW 26.5 billion. That is 9.9% lower than the same 3 months a year earlier (KRW 29.4 billion). It is 9.3% higher than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 1.6 billion, a swing from a profit of KRW 4.3 billion a year earlier. Net income (final profit after taxes and all other items) for the 3 months was a loss of KRW 0.5 billion. A year earlier it was a profit of KRW 2.4 billion.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 83.9 billion. Operating profit was KRW 1.9 billion. Net income was KRW 0.9 billion.

Comments

No comments yet

Comments from shareholders will appear here.